Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 26 May 2023, including: novel Bristol Myers Squibb Company drug shows promise in IPF; Novo Nordisk A/S’s oral semaglutide compares well with injectable in weight loss; Teva Pharmaceutical Industries Ltd. looks to innovative brands to return to growth; US setback for Intercept Pharmaceuticals, Inc.’s NASH drug; and India’s improving environment for clinical trials.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III" - Scrip, 22 May, 2023.)
(Also see "Teva Establishes Four Pillars To Prop Up Its Return-To-Growth Strategy" - Scrip, 18 May, 2023.)
(Also see "What Does The Negative FDA Review For Intercept’s OCA Hold For Other NASH Drugs?" - Scrip, 23 May, 2023.)
(Also see "India Trials Scenario: Leaders From Novartis, IQVIA, PwC Signal Winds Of Change" - Scrip, 22 May, 2023.)